The covid-19 in vivo Nanoparticle Vaccine | Abstract
Journal of Research and Development

Journal of Research and Development
Open Access

ISSN: 2311-3278

44 2039363178


The covid-19 in vivo Nanoparticle Vaccine

Thomas Prevenslik

Vaccine development in preventing CoVid-19 requires long development and testing time which is unacceptable because attendant lockdowns cause social unrest and potential World economic collapse. Instead of traditional vaccines, a CoVid-19 treatment of patients already tested positive is proposed using intravenous injections of lipid nanoparticles (NPs). The NP treatment includes only biodegradable lipid NPs in saline. In contrast, traditional vaccines include the inactivated virus, aluminum adjuvants, formaldehyde, antibiotics, and stabilizers, but in the bloodstream of the CoVid-19 patient, only live virus exists. UV light can inactivate the live virus, but no UV sources are known within the human body. In this regard, simple QED theory based on the Planck law claims atoms in NPs lack the heat capacity to conserve heat by an increase in temperature, and instead conserve heat from the blood into EM radiation at a wavelength depending on the NP size. e.g., 80 nm lipid NPs emit UVC (254 nm) radiation. In the manner of an in vivo vaccine, the NP treatment of UVC disinfection kills the live virus to produce the inactivated virus that acts as the antigen to elicit immunity to subsequent infection. Only lipid NPs in saline are included in the in vivo vaccine while traditional vaccine ingredients are excluded. What this means is the in vivo NP vaccine not only disinfects the patient of CoVid-19, but also prompts immunity to subsequent CoVid-19 infections. By controlling the NP dose, the UVC is held to low levels of collateral DNA damage in adjacent tissue allowing recovery by DNA repair systems

Published Date: 2020-10-30;